Skip to main content

Advertisement

SpringerLink
Log in

Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders

  • Leukemia (PH Wiernik, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Leukemia is the most common pediatric cancer and accounts for approximately one third of childhood malignancies. There are germline genetic alterations that significantly increase the risk of developing hematopoietic malignancies in childhood. In this review, we describe a number of these hereditary disorders and their clinical features. These predispositions to cancer syndromes can be attributed to DNA repair/genetic instability, RAS pathway dysfunction, bone marrow failure, telomeropathies, immunodeficiencies, transcription factor abnormalities, pure familial leukemia, and aneuploidy. We focus especially on acute myeloid leukemia associated with Down syndrome, but also include other hereditary syndromes in this review. Recent advances in high-throughput genotyping technology have identified new genetic variations prone to human leukemia. Understanding of the mechanism of leukemia development in these hereditary syndromes allows us to gain insight into leukemogenesis in general and suggests therapeutic strategies based on these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Institute NC: SEER (Surveillance, Epidemiology, and End Results) Cancer statistics review, 1975–2007. 2010.

  2. Seif AE. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet. 2011;204:227–44.

    Article  PubMed  Google Scholar 

  3. Malkin D, Nichols KE, Zelley K, Schiffman JD. Predisposition to pediatric and hematologic cancers: a moving target. Am Soc Clin Oncol Educ Book. 2014:e44–55.

  4. Stieglitz E, Loh ML. Genetic predispositions to childhood leukemia. Ther Adv Hematol. 2013;4:270–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Czuchlewski DR, Peterson LC. Myeloid neoplasms with germline predisposition: a new provisional entity within the World Health Organization classification. Surg Pathol Clin. 2016;9:165–76.

    Article  PubMed  Google Scholar 

  6. Kratz CP, Stanulla M, Cave H. Genetic predisposition to acute lymphoblastic leukemia: overview on behalf of the I-BFM ALL host genetic variation working group. Eur J Med Genet. 2016;59:111–5.

    Article  PubMed  Google Scholar 

  7. Moriyama T, Relling MV, Yang JJ. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood. 2015;125:3988–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. • Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugieres L, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345–52. Large clinical study of “Li-Fraumeni syndrome”

    Article  CAS  PubMed  Google Scholar 

  9. Wimmer K, Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica. 2010;95:699–701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lauper JM, Krause A, Vaughan TL, Monnat RJ Jr. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One. 2013;8:e59709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Stinco G, Governatori G, Mattighello P, Patrone P. Multiple cutaneous neoplasms in a patient with Rothmund-Thomson syndrome: case report and published work review. J Dermatol. 2008;35:154–61.

    Article  PubMed  Google Scholar 

  12. German J. Bloom’s syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet. 1997;93:100–6.

    Article  CAS  PubMed  Google Scholar 

  13. Alter BP. Cancer in Fanconi anemia, 1927–2001. Cancer. 2003;97:425–40.

    Article  PubMed  Google Scholar 

  14. Dong H, Nebert DW, Bruford EA, Thompson DC, Joenje H, Vasiliou V. Update of the human and mouse Fanconi anemia genes. Human Genomics. 2015;9:32.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101:822–6.

    Article  CAS  PubMed  Google Scholar 

  16. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87:423–38.

    CAS  PubMed  Google Scholar 

  17. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994;70:969–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in diamond Blackfan anemia: a report from the diamond Blackfan anemia registry. Blood. 2012;119:3815–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Noris P, Favier R, Alessi MC, Geddis AE, Kunishima S, Heller PG, Giordano P, Niederhoffer KY, Bussel JB, Podda GM, et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood. 2013;122:1987–9.

    Article  CAS  PubMed  Google Scholar 

  20. Savage SA. Dyskeratosis congenita. In GeneReviews(R). Edited by Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, et al.: University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

  21. Godley LA. Inherited predisposition to acute myeloid leukemia. Semin Hematol. 2014;51:306–21.

    Article  PubMed  Google Scholar 

  22. • Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123:809–21. Excellent review article of “GATA2 deficiency”

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351:2403–7.

    Article  CAS  PubMed  Google Scholar 

  24. Saliba J, Saint-Martin C, Di Stefano A, Lenglet G, Marty C, Keren B, Pasquier F, Valle VD, Secardin L, Leroy G, et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet. 2015;47:1131–40.

    Article  CAS  PubMed  Google Scholar 

  25. Morrissette JJD, Wertheim G, Olson T. Familial monosomy 7 syndrome. In GeneReviews(R). Edited by Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, et al.: University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

  26. •• Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–9. Comprehensive genetic study first reporting the mutations of epigenetic factor in “Down syndrome related myeoid disorders”

    Article  CAS  PubMed  Google Scholar 

  27. Saida S. Evolution of myeloid leukemia in children with Down syndrome. Int J Hematol. 2016;103:365–72.

    Article  CAS  PubMed  Google Scholar 

  28. Hasle H, Clausen N, Pedersen B, Bendix-Hansen K. Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. Cancer Genet Cytogenet. 1995;79:79–81.

    Article  CAS  PubMed  Google Scholar 

  29. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability—an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220–8.

    Article  CAS  PubMed  Google Scholar 

  30. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747–52.

    Article  CAS  PubMed  Google Scholar 

  31. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–62.

    CAS  PubMed  Google Scholar 

  32. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–8.

    Article  CAS  PubMed  Google Scholar 

  33. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747–9.

    Article  CAS  PubMed  Google Scholar 

  34. Vasen HF, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, Entz-Werle N, Goldberg Y, Ilencikova D, Kratz CP, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European consortium “care for CMMR-D” (C4CMMR-D). J Med Genet. 2014;51:283–93.

    Article  CAS  PubMed  Google Scholar 

  35. Sijmons RH, Hofstra RM. Review: clinical aspects of hereditary DNA mismatch repair gene mutations. DNA Repair (Amst). 2016;38:155–62.

    Article  CAS  Google Scholar 

  36. Mehta PA, Tolar J. Fanconi anemia. In GeneReviews(R). Edited by Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, et al.: University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

  37. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.

    Article  CAS  PubMed  Google Scholar 

  38. Niemeyer CM. RAS diseases in children. Haematologica. 2014;99:1653–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood. 2015;125:1083–90.

    Article  CAS  PubMed  Google Scholar 

  40. Bagby GC, Meyers G. Bone marrow failure as a risk factor for clonal evolution: prospects for leukemia prevention. Hematology Am Soc Hematol Educ Program. 2007:40–6.

  41. Dror Y, Freedman MH. Shwachman-diamond syndrome. Br J Haematol. 2002;118:701–13.

    Article  PubMed  Google Scholar 

  42. Freedman MH, Bonilla MA, Fier C, Bolyard AA, Scarlata D, Boxer LA, Brown S, Cham B, Kannourakis G, Kinsey SE, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood. 2000;96:429–36.

    CAS  PubMed  Google Scholar 

  43. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Fier C, Freedman M, Kannourakis G, Kinsey S, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107:4628–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Rosenberg PS, Alter BP, Link DC, Stein S, Rodger E, Bolyard AA, Aprikyan AA, Bonilla MA, Dror Y, Kannourakis G, et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol. 2008;140:210–3.

    CAS  PubMed  Google Scholar 

  45. Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost. 2011;37:673–81.

    Article  CAS  PubMed  Google Scholar 

  46. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after 15 years of follow-up. Blood. 2016;128:334.

    Google Scholar 

  47. Mirabello L, Macari ER, Jessop L, Ellis SR, Myers T, Giri N, Taylor AM, McGrath KE, Humphries JM, Ballew BJ, et al. Whole-exome sequencing and functional studies identify RPS29 as a novel gene mutated in multicase diamond-Blackfan anemia families. Blood. 2014;124:24–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Wang R, Yoshida K, Toki T, Sawada T, Uechi T, Okuno Y, Sato-Otsubo A, Kudo K, Kamimaki I, Kanezaki R, et al. Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in diamond-Blackfan anaemia. Br J Haematol. 2015;168:854–64.

    Article  CAS  PubMed  Google Scholar 

  49. Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP, Tolar J. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant. 2011;46:98–104.

    Article  CAS  PubMed  Google Scholar 

  50. Shimizu R, Yamamoto M. GATA-related hematologic disorders. Exp Hematol. 2016;44:696–705.

    Article  CAS  PubMed  Google Scholar 

  51. Saida S, Umeda K, Yasumi T, Matsumoto A, Kato I, Hiramatsu H, Ohara O, Heike T, Adachi S. Successful reduced-intensity stem cell transplantation for GATA2 deficiency before progression of advanced MDS. Pediatr Transplant. 2016;20:333–6.

    Article  CAS  PubMed  Google Scholar 

  52. Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, Singh J, Padgett RA, Gu X, Phillips JG, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:658–70.

    Article  CAS  PubMed  Google Scholar 

  53. Seghezzi L, Maserati E, Minelli A, Dellavecchia C, Addis P, Locatelli F, Angioni A, Balloni P, Miano C, Cavalli P, et al. Constitutional trisomy 8 as first mutation in multistep carcinogenesis: clinical, cytogenetic, and molecular data on three cases. Genes Chromosomes Cancer. 1996;17:94–101.

    Article  CAS  PubMed  Google Scholar 

  54. Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, Anderson P, Mason CA, Collins JS, Kirby RS, et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004–2006. Birth Defects Res A Clin Mol Teratol. 2010;88:1008–16.

    Article  CAS  PubMed  Google Scholar 

  55. Roizen NJ, Patterson D. Down’s syndrome. Lancet. 2003;361:1281–9.

    Article  PubMed  Google Scholar 

  56. Paulsson K, Johansson B. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathol Biol (Paris). 2007;55:37–48.

    Article  CAS  Google Scholar 

  57. Saumell S, Sole F, Arenillas L, Montoro J, Valcarcel D, Pedro C, Sanzo C, Luno E, Gimenez T, Arnan M, et al. Trisomy 8, a cytogenetic abnormality in myelodysplastic syndromes, is constitutional or not? PLoS One. 2015;10:e0129375.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Fong CT, Brodeur GM. Down’s syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet. 1987;28:55–76.

    Article  CAS  PubMed  Google Scholar 

  59. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165–9.

    Article  CAS  PubMed  Google Scholar 

  60. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9:139–49.

    Article  CAS  PubMed  Google Scholar 

  61. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128–31.

    Article  CAS  PubMed  Google Scholar 

  62. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, Ravindranath Y, Dahl G, Weinstein HJ. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s oncology group (COG) study POG-9481. Blood. 2006;107:4606–13.

    Article  CAS  PubMed  Google Scholar 

  63. Hitzler JK. Acute megakaryoblastic leukemia in Down syndrome. Pediatr Blood Cancer. 2007;49:1066–9.

    Article  PubMed  Google Scholar 

  64. Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O’Marcaigh A, Wynn R, Stevens R, Addison M, King D, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480–9.

    Article  CAS  PubMed  Google Scholar 

  65. Groet J, McElwaine S, Spinelli M, Rinaldi A, Burtscher I, Mulligan C, Mensah A, Cavani S, Dagna-Bricarelli F, Basso G, et al. Acquired mutations in GATA1 in neonates with Down’s syndrome with transient myeloid disorder. Lancet. 2003;361:1617–20.

    Article  CAS  PubMed  Google Scholar 

  66. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–52.

    Article  CAS  PubMed  Google Scholar 

  67. Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981–6.

    Article  CAS  PubMed  Google Scholar 

  68. Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, Taki T, Mitui T, Koike K, Kato K, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102:2960–8.

    Article  CAS  PubMed  Google Scholar 

  69. Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A, Vallance G, Perkins K, Marchi E, McGowan S, et al. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood. 2013;122:3908–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Carpenter E, Valverde-Garduno V, Sternberg A, Mitchell C, Roberts I, Vyas P, Vora A. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol. 2005;128:548–51.

    Article  CAS  PubMed  Google Scholar 

  71. Nikolaev SI, Santoni F, Vannier A, Falconnet E, Giarin E, Basso G, Hoischen A, Veltman JA, Groet J, Nizetic D, et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood. 2013;122:554–61.

    Article  CAS  PubMed  Google Scholar 

  72. Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27:214–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Ma SK, Wan TS, Cheuk AT, Fung LF, Chan GC, Chan SY, Ha SY, Chan LC. Characterization of additional genetic events in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion: a molecular cytogenetics study. Leukemia. 2001;15:1442–7.

    Article  CAS  PubMed  Google Scholar 

  74. Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BE, Kinsey SE, Eden TO, Vora AJ, Mitchell CD, Harrison CJ. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood. 2007;109:2327–30.

    Article  CAS  PubMed  Google Scholar 

  75. Antonarakis SE. Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet. 2017;18:147–63.

    Article  CAS  PubMed  Google Scholar 

  76. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012;122:948–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Saida S, Watanabe K, Sato-Otsubo A, Terui K, Yoshida K, Okuno Y, Toki T, Wang R, Shiraishi Y, Miyano S, et al. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome. Blood. 2013;121:4377–87.

    Article  CAS  PubMed  Google Scholar 

  78. Muramatsu H, Okuno Y, Yoshida K, Shiraishi Y, Doisaki S, Narita A, Sakaguchi H, Kawashima N, Wang X, Xu Y, et al. Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes. Genet Med. 2017;

Download references

Acknowledgements

This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Young Scientists (B) Research Project Number 26860795.

Author information

Authors and Affiliations

  1. Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bldg 49, RM 4A25 49 Convent DR, Bethesda, MD, 20892, USA

    Satoshi Saida MD, PhD

  2. Department of Pediatrics, Kyoto University Hospital, Kyoto, Japan

    Satoshi Saida MD, PhD

  3. Japan Society for the Promotion of Science, Tokyo, Japan

    Satoshi Saida MD, PhD

Authors
  1. Satoshi Saida MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Saida MD, PhD.

Ethics declarations

Conflict of Interest

The author declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Leukemia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saida, S. Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders. Curr. Treat. Options in Oncol. 18, 41 (2017). https://doi.org/10.1007/s11864-017-0485-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0485-x

Keywords

Search

Navigation